JAK inhibitors are new targeted synthetic DMARDs used in treatment for RA that reduce inflammation by inhibiting the JAK-STAT pathway to decrease the production of several pro-inflammatory cytokines. This evidence concerns the gene SOAT1 and rheumatoid arthritis.